Archives
SAR405: Selective ATP-Competitive Vps34 Inhibitor for Pre...
SAR405: Precision Autophagy Inhibition via Selective ATP-Competitive Vps34 Targeting
Principle Overview: Selective Vps34 Inhibition and the Autophagy-Lysosome Axis
SAR405 is a next-generation, highly selective ATP-competitive inhibitor of Vps34, a class III phosphoinositide 3-kinase (PI3K) isoform pivotal for autophagy regulation and vesicle trafficking. With a dissociation constant (Kd) of 1.5 nM and an IC50 of 1 nM against human recombinant Vps34, SAR405 delivers potent, target-specific inhibition that does not affect class I/II PI3Ks or mTOR up to 10 μM. By occupying the ATP binding cleft of Vps34, SAR405 disrupts kinase activity, triggering profound downstream effects: impaired late endosome-lysosome function, accumulation of swollen late endosome-lysosomes, and defective cathepsin D maturation. The result is a blockade of autophagosome formation and robust autophagy inhibition, as validated in GFP-LCLC3 HeLa and H1299 cells.
This high degree of selectivity and potency positions SAR405 as a unique pharmacological tool for probing the complexities of autophagy, the Vps34 kinase signaling pathway, and vesicle trafficking modulation in diverse biological systems. Its application in cancer research and neurodegenerative disease models enables granular dissection of lysosome function impairment and autophagosome formation blockade, facilitating breakthroughs in disease mechanism studies and therapeutic innovation.
Step-by-Step Workflow: Optimized Experimental Protocols for SAR405
1. Preparation and Storage
- Stock Solution: Dissolve SAR405 in DMSO at concentrations >10 mM. For ethanol solubilization, use ultrasonic assistance to maximize yield. SAR405 is insoluble in water.
- Storage: Aliquot and store stock solutions below -20°C for several months. Avoid repeated freeze-thaw cycles and long-term storage of working solutions to preserve compound integrity.
2. Cell-Based Assays
- Cell Line Selection: SAR405 has demonstrated efficacy in GFP-LCLC3 HeLa and H1299 cell lines. Its high selectivity allows integration into diverse human and murine models (e.g., primary neurons, cancer spheroids).
- Treatment Regimen: Typical working concentrations range from 10 nM to 1 μM, depending on cell type and endpoint. Begin with 100 nM for baseline autophagy inhibition.
- Control Conditions: Include DMSO-only and, if relevant, mTOR inhibitor (e.g., everolimus) co-treatment arms to dissect pathway crosstalk and potential synergistic effects.
3. Readout and Analysis
- Autophagosome Formation: Use LC3-GFP puncta quantification or immunoblotting for LC3-II as primary readouts. SAR405 typically induces a >90% reduction in autophagosome formation at 100 nM within 1–4 hours of treatment (see comparative performance).
- Lysosome Function: Assess late endosome-lysosome morphology (e.g., LAMP1/LAMP2 immunofluorescence) and cathepsin D maturation via western blot. Expect accumulation of swollen vesicles and impaired protease processing.
- Vesicle Trafficking: Track trafficking cargo (e.g., dextran uptake assays) to evaluate vesicle dynamics under Vps34 inhibition.
4. Protocol Enhancements
- Synergy Studies: Co-treat with mTOR inhibitors (e.g., everolimus) to explore synergistic autophagy blockade. SAR405 plus mTOR inhibition often yields additive or synergistic suppression of autophagic flux (see extension).
- Time-Course Experiments: Conduct time-resolved analyses (e.g., 0.5, 1, 2, 4, and 8 hours) to map the kinetics of autophagy inhibition and vesicle trafficking disruption.
- Energy Stress Models: Combine SAR405 with nutrient deprivation or mitochondrial stressors to interrogate Vps34’s role in cellular energy responses, leveraging recent insights into AMPK-ULK1 signaling (Park et al., 2023).
Advanced Applications and Comparative Advantages
1. Cancer and Neurodegenerative Disease Modeling
SAR405’s exquisite selectivity and potency make it an indispensable tool in cancer research and neurodegenerative disease models. By enabling precise autophagy inhibition and vesicle trafficking modulation, SAR405 allows researchers to:
- Dissect the contribution of Vps34 kinase signaling to tumor cell survival, growth, and response to therapy.
- Model lysosome function impairment implicated in neurodegenerative pathologies, such as Parkinson’s and Alzheimer’s disease, where autophagy flux is disrupted.
- Explore synthetic lethal interactions in tumor models by combining SAR405 with metabolic or chemotherapeutic agents.
For a strategic discussion on SAR405’s transformative impact in disease modeling, see "SAR405 and the Future of Autophagy Research: Redefining V...", which complements this workflow-centric perspective by delving into translational implications and experimental design innovations.
2. Mechanistic Dissection of the AMPK-ULK1-Vps34 Axis
Recent paradigm-shifting research has unsettled the classic view of AMPK as a straightforward autophagy activator. As demonstrated by Park et al. (2023), AMPK can inhibit ULK1, thereby suppressing autophagy initiation, especially during energy crisis. SAR405’s ability to block Vps34-dependent autophagosome formation enables precise mapping of the downstream consequences of AMPK-ULK1 signaling perturbations. Integrating SAR405 into energy stress models (e.g., glucose starvation, mitochondrial dysfunction) offers a robust approach to validate or challenge emerging mechanisms in autophagy regulation.
This capacity to couple pharmacological Vps34 inhibition with genetic or biochemical manipulation of AMPK/ULK1 represents a major advance over conventional PI3K or mTOR inhibitors, which lack equivalent specificity and can confound pathway analysis.
3. Comparative Advantages Over Traditional Inhibitors
- Nanomolar Potency and Selectivity: SAR405 achieves complete Vps34 inhibition at 1–100 nM, with no effect on class I/II PI3Ks or mTOR up to 10 μM, reducing off-target artifacts.
- Pathway-Specific Readouts: Unlike broad-spectrum PI3K inhibitors, SAR405 enables unambiguous attribution of phenotypes to Vps34 inhibition, streamlining interpretation in complex cellular systems.
- Synergistic Combinations: SAR405’s compatibility with mTOR inhibitors and metabolic stressors unlocks new avenues for combinatorial studies of autophagy inhibition in therapeutic contexts (see extension).
Troubleshooting and Optimization Tips
- Poor Solubility: If SAR405 precipitates, ensure use of DMSO (>10 mM) or ethanol with ultrasonic assistance. Avoid water as a solvent. Filter sterilize stock solutions if required for cell culture.
- Variable Inhibition: Confirm compound integrity by LC-MS or NMR if unexpected results occur. Check for DMSO degradation or repeated freeze-thaw cycles.
- Non-Specific Effects: Use concentrations ≤1 μM and include DMSO-only controls to distinguish on-target from off-target phenomena.
- Timing Issues: Time-course optimization is crucial. Some cell types may require extended incubation (up to 8 hours) for maximal autophagy inhibition.
- Readout Sensitivity: Employ multiple, orthogonal readouts (e.g., LC3-II immunoblot, GFP-LC3 puncta, lysosomal markers) to confirm autophagy inhibition and lysosome function impairment.
- Interpreting Energy Stress Models: When using SAR405 in nutrient deprivation or mitochondrial dysfunction assays, consider recent findings that AMPK may inhibit rather than activate ULK1 and autophagy (Park et al., 2023). SAR405 can help clarify whether observed phenotypes stem from Vps34-dependent or -independent mechanisms.
Future Outlook: SAR405 in Next-Generation Disease Modeling
SAR405’s robust pharmacological profile is catalyzing a new era in autophagy and vesicle trafficking research. By enabling precise, pathway-specific inhibition of Vps34, SAR405 is empowering the development of advanced disease models for cancer and neurodegenerative disorders, supporting both mechanistic dissection and preclinical drug discovery. Its integration with emerging paradigms in AMPK-ULK1 signaling—such as those described in Park et al. (2023)—will further refine our understanding of cellular energy stress responses and autophagy regulation.
For researchers seeking to explore the full translational and mechanistic potential of SAR405, resources like "SAR405: Redefining Vps34 Inhibition for Precision Autopha..." (which extends this article’s focus to next-generation applications) and "SAR405: Selective ATP-Competitive Vps34 Inhibitor for Aut..." (which provides additional data-driven insights) are invaluable.
To incorporate SAR405 into your experimental pipeline and stay at the forefront of autophagy research, visit the SAR405 product page for detailed specifications and ordering information.